JP4397693B2 - N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 - Google Patents
N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 Download PDFInfo
- Publication number
- JP4397693B2 JP4397693B2 JP2003576402A JP2003576402A JP4397693B2 JP 4397693 B2 JP4397693 B2 JP 4397693B2 JP 2003576402 A JP2003576402 A JP 2003576402A JP 2003576402 A JP2003576402 A JP 2003576402A JP 4397693 B2 JP4397693 B2 JP 4397693B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- alkyl
- aroyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002253 acid Substances 0.000 title claims description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title description 16
- 230000015572 biosynthetic process Effects 0.000 title description 5
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 54
- -1 aroyl compound Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000003435 aroyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 150000001408 amides Chemical group 0.000 claims description 5
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000006371 dihalo methyl group Chemical group 0.000 claims description 5
- 125000004982 dihaloalkyl group Chemical group 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000004970 halomethyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 150000002825 nitriles Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 5
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 claims 2
- 239000003205 fragrance Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 150000004885 piperazines Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- 238000007142 ring opening reaction Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 0 *[C@](CNc1ccccn1)N Chemical compound *[C@](CNc1ccccn1)N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- IUXBPLUZEPYPGY-UHFFFAOYSA-N CS(OCCN(CCOS(C)(=O)=O)c1cccc2c1OCCO2)(=O)=O Chemical compound CS(OCCN(CCOS(C)(=O)=O)c1cccc2c1OCCO2)(=O)=O IUXBPLUZEPYPGY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DMLRSJNZORFCBD-UHFFFAOYSA-N Nc1cccc2c1OCCO2 Chemical compound Nc1cccc2c1OCCO2 DMLRSJNZORFCBD-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- YWWMGXGZLQWZGA-UHFFFAOYSA-N OCCN(CCO)c1cccc2c1OCCO2 Chemical compound OCCN(CCO)c1cccc2c1OCCO2 YWWMGXGZLQWZGA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LRHVEGCJASOOIG-UHFFFAOYSA-N acetic acid;bromoethane Chemical compound CCBr.CC(O)=O LRHVEGCJASOOIG-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- WOBXIZDZSBFOEN-UHFFFAOYSA-N aniline 2,3-dihydro-1,4-benzodioxine Chemical compound NC1=CC=CC=C1.O1CCOC2=C1C=CC=C2 WOBXIZDZSBFOEN-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- ROIPBPWWXWOVSW-UHFFFAOYSA-N bromo(chloro)methanesulfonic acid Chemical compound OS(=O)(=O)C(Cl)Br ROIPBPWWXWOVSW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical group S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
N−アリールピペラジンの製造方法およびそのための中間体に関する。
式A:
で示されるピペラジンは、強力な5HT1A受容体結合剤である。米国特許第6,127,357号は、中枢神経系(CNS)障害の治療に有用なピペラジン誘導体を教示している。かかるピペラジンのエナンチオマーは、5HT1A受容体に対して異なる結合能力を示しうる。したがって、これらの有効性、選択性および代謝効果は、異なりうる。WO9703982は、かかるピペラジンのある種のエナンチオマーが、改善された5HT1A結合アフィニティーおよび生物学的利用能を示すことを教示している。したがって、効果的、操作が容易で、安価かつ安全な、光学的に好ましいピペラジンを製造する別の方法が所望されている。
WO97/37655およびCignarella et al., Farmaco Ed. Sci.; 31; 1976; 194, 196は、N1−(2’ピリジル)−1,2−プロパン−ジアミンの調製および反応を議論している。
本発明は、式IIで示されるN1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の製造方法であって、式Iで示される化合物をNH2R’と反応させることを含む方法である:
さらに、本発明は、式IIで示される化合物およびその光学異性体を含む。
式IIで示される化合物を水素化して、R’をHに変換し、すでにHである場合、ついで、酸を用いて加水分解して、式III:
で示される化合物を形成することができる。
本発明のさらなる態様は、N−アリールピペラジンの新規製造方法およびそのための中間体を提供することである。
本発明の別の態様は、式IIで示される化合物の新規製造方法を提供することである。
本発明の別の態様および利点は、本明細書に記載の発明の詳細な説明および請求の範囲から当業者には明らかだろう。
本発明の好ましい具体例は、N1−(2’−ピリジル)−1,2−プロパンジアミンスルファミン酸を用いるN−アリールピペラジンの新規製造方法、特に、アリールが4−シアノフェニルである式VIを有するN−アリールピペラジンの製造方法である。本発明の別の好ましい具体例は、N−アリールピペラジンの調製のための固体中間体を容易に単離するための、N1−(2’−ピリジル)−1,2−プロパンジアミンスルファミン酸の新規製造方法、およびN−アリールピペラジンの調製に有用であるその新規誘導体である。
本発明は、一工程、立体選択的および収束方法での、光学的に活性なN,N’−二置換ピペラジンの合成に有用であるだろうN1−(2’ピリジル)−1,2−プロパン−ジアミンスルファミン酸を用いる方法を提供する。光学的に活性なN,N’−二置換ピペラジンは、5−HT1A(セロトニン)受容体アンタゴニストとして活性である。
式IVで示される化合物において、Lはいずれの適当な脱離基であってもよい。当業者は、どの基が本発明の実施において適しているか容易に決定できるだろう。かかる適当な脱離基の例としては、クロロ、ブロモ、メシラート、トシラートおよびp−ブロモフェニルスルホニルオキシ基が挙げられる。
酸、塩基または溶媒の存在が、本発明の反応に必要であるる場合、当該分野で公知のいずれの酸、塩基または溶媒を用いることができる当業者は、容易に、本発明を行うにあたって用いるべき、適当な溶媒、酸および塩基を同定することができるだろう。
Rf=0.31(10:1CHCl3:CH3OH);
1H NMR(DMSO)δ9.77(bs,1H,OH)、7.15−8.0(m,13H)、6.7−6.8(m,1H)、5.81(bs,1H,NH)、4.1−4.3(m,2H)、3.4(m,2H)、1.3(d,J=4.8Hz,2H);
13CNMR(DMSO)δ155.2、146.5、137.4、136.4、129.4、129.3、129.2、129.0、128.8、128.1、127.8、127.7、127.5、127.5、126.3、116.0、114.8、62.4、57.3、53.2、50.1、14.4;
IR(KBr):νmax3432、3057、3010、2931、2836、2663、2508、2330、1599、1565、1500、1474、1433cm−1;
CHN(計算値)C63.48 H5.79 N10.57、CHN(実測値)C63.38 H5.74 N10.52;
MP=203.5〜208℃
無水アセトニトリル(1mL)中の式Xで示されるジメシラート(57mg、0.14mmol)の溶液に、アミノピリジン(20mg、0.13mmol)、炭酸カリウム(52mg、0.38mmol)および臭化リチウム(26mg、0.30mmol)を加えた。反応混合物を15時間N2下で加熱還流し、ついで、室温に冷却し、ついで、セライトのパッドで濾過する。ついで、パッドをアセトニトリルで洗浄する。合した有機層をNa2SO4で乾燥し、濾過し、減圧下で濃縮して、黄色油として52g(105%)のピペラジンXI(GC/MSにより92%面積%)を得た。
Claims (15)
- Rがメチルである、請求項1記載の方法。
- アリールが4−シアノフェニルである、請求項7記載の方法。
- 式II:
で示される化合物を式III:
a)R’がH以外である場合、式IIで示される化合物を水素化して、R’をHに変換すること;および
b)R’がHである式IIで示される化合物を酸加水分解して、式IIIで示される化合物を形成することを含む方法。 - R’が、H、ベンジルおよびベンズヒドリルからなる群から選択される、請求項14記載の化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36345702P | 2002-03-12 | 2002-03-12 | |
PCT/US2003/007228 WO2003078396A1 (en) | 2002-03-12 | 2003-03-10 | Preparation of n1-(2’-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005526088A JP2005526088A (ja) | 2005-09-02 |
JP4397693B2 true JP4397693B2 (ja) | 2010-01-13 |
Family
ID=28041771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003576402A Expired - Fee Related JP4397693B2 (ja) | 2002-03-12 | 2003-03-10 | N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 |
Country Status (27)
Country | Link |
---|---|
US (1) | US6784294B2 (ja) |
EP (2) | EP1483243B1 (ja) |
JP (1) | JP4397693B2 (ja) |
KR (1) | KR20040091720A (ja) |
CN (1) | CN100341854C (ja) |
AR (1) | AR038932A1 (ja) |
AT (2) | ATE360002T1 (ja) |
AU (1) | AU2003220122A1 (ja) |
BR (1) | BR0308315A (ja) |
CA (1) | CA2477886A1 (ja) |
CY (1) | CY1106677T1 (ja) |
DE (2) | DE60330199D1 (ja) |
DK (1) | DK1483243T3 (ja) |
EC (1) | ECSP045291A (ja) |
ES (2) | ES2283762T3 (ja) |
HK (1) | HK1068618A1 (ja) |
IL (1) | IL163829A0 (ja) |
MX (1) | MXPA04008731A (ja) |
NO (1) | NO20044049L (ja) |
NZ (1) | NZ535170A (ja) |
PT (1) | PT1483243E (ja) |
RU (1) | RU2314294C2 (ja) |
SI (1) | SI1483243T1 (ja) |
TW (1) | TWI288642B (ja) |
UA (1) | UA80272C2 (ja) |
WO (1) | WO2003078396A1 (ja) |
ZA (1) | ZA200408213B (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
JP5080716B2 (ja) | 2001-07-20 | 2012-11-21 | サイコジェニックス・インコーポレーテッド | 注意欠陥・多動性障害の治療 |
TWI288642B (en) | 2002-03-12 | 2007-10-21 | Wyeth Corp | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
US7361773B2 (en) * | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
NZ535169A (en) * | 2002-03-12 | 2006-03-31 | Wyeth Corp | Process for making chiral 1,4-disubstituted piperazines |
US20050209245A1 (en) * | 2004-03-19 | 2005-09-22 | Wyeth | Process for preparing N-aryl-piperazine derivatives |
US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
JP2008531694A (ja) * | 2005-03-01 | 2008-08-14 | ワイス | 結晶性および非晶性4−シアノ−n−{(2r)−2−[4−(2,3−ジヒドロ−ベンゾ[1,4]ジオキシン−5−イル)−ピペラジン−1−イル]−プロピル}−n−ピリジン−2−イル−ベンズアミド塩酸塩 |
CN102791691B (zh) | 2010-03-12 | 2015-06-03 | 日本曹达株式会社 | 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法 |
EP2602248A1 (en) | 2011-12-05 | 2013-06-12 | University Of Leicester | Novel pyrrole compounds |
GB201310126D0 (en) * | 2013-06-06 | 2013-07-24 | Univ Leicester | Novel pyrrole derivatives |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE81975T1 (de) | 1984-12-21 | 1992-11-15 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
JPH01125357A (ja) | 1987-11-06 | 1989-05-17 | Dainippon Pharmaceut Co Ltd | トリペプチドの誘導体 |
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
WO1994024115A1 (en) | 1993-04-16 | 1994-10-27 | Santen Pharmaceutical Co., Ltd. | Novel piperazine derivative |
GB9411099D0 (en) * | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
AU2622595A (en) | 1994-06-03 | 1996-01-04 | John Wyeth & Brother Limited | Novel processes and intermediates for the preparation of piperazine derivatives |
GB9514901D0 (en) * | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3拮抗薬 |
TWI288642B (en) | 2002-03-12 | 2007-10-21 | Wyeth Corp | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
CN1982307A (zh) * | 2002-03-12 | 2007-06-20 | 惠氏公司 | 合成手性n-芳基哌嗪的方法 |
-
2003
- 2003-03-10 TW TW092105099A patent/TWI288642B/zh not_active IP Right Cessation
- 2003-03-10 RU RU2004130314/04A patent/RU2314294C2/ru not_active IP Right Cessation
- 2003-03-10 MX MXPA04008731A patent/MXPA04008731A/es active IP Right Grant
- 2003-03-10 ES ES03716415T patent/ES2283762T3/es not_active Expired - Lifetime
- 2003-03-10 KR KR10-2004-7014252A patent/KR20040091720A/ko active IP Right Grant
- 2003-03-10 CA CA002477886A patent/CA2477886A1/en not_active Abandoned
- 2003-03-10 AT AT03716415T patent/ATE360002T1/de not_active IP Right Cessation
- 2003-03-10 SI SI200330817T patent/SI1483243T1/sl unknown
- 2003-03-10 EP EP03716415A patent/EP1483243B1/en not_active Expired - Lifetime
- 2003-03-10 PT PT03716415T patent/PT1483243E/pt unknown
- 2003-03-10 DK DK03716415T patent/DK1483243T3/da active
- 2003-03-10 DE DE60330199T patent/DE60330199D1/de not_active Expired - Lifetime
- 2003-03-10 ES ES07007755T patent/ES2334836T3/es not_active Expired - Lifetime
- 2003-03-10 AU AU2003220122A patent/AU2003220122A1/en not_active Abandoned
- 2003-03-10 NZ NZ535170A patent/NZ535170A/xx unknown
- 2003-03-10 US US10/385,337 patent/US6784294B2/en not_active Expired - Fee Related
- 2003-03-10 JP JP2003576402A patent/JP4397693B2/ja not_active Expired - Fee Related
- 2003-03-10 DE DE60313301T patent/DE60313301T2/de not_active Expired - Lifetime
- 2003-03-10 BR BR0308315-2A patent/BR0308315A/pt not_active IP Right Cessation
- 2003-03-10 EP EP07007755A patent/EP1801103B1/en not_active Expired - Lifetime
- 2003-03-10 AT AT07007755T patent/ATE449073T1/de not_active IP Right Cessation
- 2003-03-10 CN CNB038058421A patent/CN100341854C/zh not_active Expired - Fee Related
- 2003-03-10 IL IL16382903A patent/IL163829A0/xx unknown
- 2003-03-10 WO PCT/US2003/007228 patent/WO2003078396A1/en active IP Right Grant
- 2003-03-11 AR ARP030100833A patent/AR038932A1/es unknown
- 2003-10-03 UA UA20041008214A patent/UA80272C2/uk unknown
-
2004
- 2004-09-10 EC EC2004005291A patent/ECSP045291A/es unknown
- 2004-09-24 NO NO20044049A patent/NO20044049L/no not_active Application Discontinuation
- 2004-10-11 ZA ZA200408213A patent/ZA200408213B/en unknown
-
2005
- 2005-02-02 HK HK05100856A patent/HK1068618A1/xx not_active IP Right Cessation
-
2007
- 2007-06-26 CY CY20071100843T patent/CY1106677T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI109122B (fi) | Menetelmä verisuonia supistavana aineena käyttökelpoisten [(bentsodioksaani-, bentsofuraani- tai bentsopyraani)-alkyyliamino]alkyylisubstituoitujen guanidiinien valmistamiseksi ja välituote | |
KR100359393B1 (ko) | 5-ht1a 길항제로서의 피페라진유도체 및 이의 제조방법 | |
JP4397693B2 (ja) | N1−(2’−ピリジル)−1,2−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 | |
NZ233398A (en) | Aryl- or heteroaryl-substituted piperazine derivatives and pharmaceutical compositions | |
US20050014792A1 (en) | Process for preparation of pyridine derivatives | |
JP2013537875A5 (ja) | ||
CA2477892C (en) | Process for synthesizing chiral n-aryl piperazines | |
US7361773B2 (en) | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines | |
US7091349B2 (en) | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution | |
JPH09143166A (ja) | 新規な縮合インダン誘導体及びその塩 | |
JP2012153674A (ja) | ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体 | |
JP2002255915A (ja) | ミドドリンの製法 | |
US8236954B2 (en) | Processes for preparing benzimidazole thiophenes | |
US6063784A (en) | Heteroaryloxyethylamines, method of preparation, application as medicine and pharmaceutical compositions containing them | |
US6150417A (en) | Phenoxyethylamine derivatives, method of preparation application as medicine and pharmaceutical compositions containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091006 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091021 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121030 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |